Kylo-0603 / Sino Biopharm, Kylonova Biopharma, Hygieia Pharmaceuticals - LARVOL DELTA

Dose Escalation Study of Kylo-0603 in Healthy Subjects (clinicaltrials.gov) - P1 | N=132 | Completed | Sponsor: Kylonova (Xiamen) Biopharma co., LTD. | Recruiting ➔ Completed

First-in-human • Trial completion • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis

Kylo-0603-IIa-01: A Phase 2a Study of Kylo-0603 Capsule in Participants With Metabolic Dysfunction Associated Steatotic Liver Disease (MASLD) (clinicaltrials.gov) - P2 | N=120 | Not yet recruiting | Sponsor: Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.

New P2 trial • Hepatology • Metabolic Disorders • Metabolic Dysfunction-Associated Steatotic Liver Disease

Dose Escalation Study of Kylo-0603 in Healthy Subjects (clinicaltrials.gov) - P1 | N=124 | Recruiting | Sponsor: Kylonova (Xiamen) Biopharma co., LTD.

First-in-human • New P1 trial • Hepatology • Metabolic Dysfunction-Associated Steatohepatitis